Edition:
India

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

23.06USD
17 Jun 2019
Change (% chg)

$1.62 (+7.56%)
Prev Close
$21.44
Open
$22.10
Day's High
$23.48
Day's Low
$21.93
Volume
104,018
Avg. Vol
60,252
52-wk High
$45.61
52-wk Low
$18.56

Latest Key Developments (Source: Significant Developments)

Deciphera And Zai Lab Announce Exclusive License Agreement For Ripretinib In Greater China
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. AND ZAI LAB LIMITED ANNOUNCE AN EXCLUSIVE LICENSE AGREEMENT FOR RIPRETINIB IN GREATER CHINA.ZAI LAB LTD - DECIPHERA TO RECEIVE $20 MILLION UPFRONT CASH PAYMENT, UP TO $185 MILLION IN POTENTIAL FUTURE MILESTONES AND ROYALTIES.ZAI LAB LTD - ZAI LAB TO LEAD DEVELOPMENT AND COMMERCIALIZATION OF RIPRETINIB IN GREATER CHINA.ZAI LAB - DECIPHERA INTENDS TO EXPAND RIPRETINIB DEVELOPMENT PROGRAM IN GIST BY POTENTIALLY ADDING CHINA SITES TO ONGOING GLOBAL PHASE 3 INTRIGUE STUDY.ZAI LAB LTD - WOULD PAY DECIPHERA ROYALTIES FROM LOW TO HIGH TEENS ON ANNUAL NET SALES OF RIPRETINIB IN GREATER CHINA.  Full Article

Deciphera Pharmaceuticals Q4 Loss Per Share $0.86
Friday, 15 Mar 2019 

March 14 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.86.Q4 EARNINGS PER SHARE ESTIMATE $-0.73 -- REFINITIV IBES DATA.ENDED 2018 WITH CASH AND CASH EQUIVALENTS OF $294 MILLION.  Full Article

Deciphera Pharmaceuticals Says CEO And President Michael D. Taylor To Retire
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Deciphera Pharmaceuticals Inc ::SAYS CEO AND PRESIDENT MICHAEL D. TAYLOR TO RETIRE.SAYS STEVE HOERTER APPOINTED CEO AND PRESIDENT.OUTGOING CEO MICHAEL TAYLOR TO CONTINUE TO SERVE AS A MEMBER OF BOARD OF DIRECTORS.  Full Article

Deciphera Announces Positive, Preliminary Clinical Data For Ongoing Phase 1 Clinical Study With DCC-3014
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS ANNOUNCES POSITIVE, PRELIMINARY, TOP-LINE CLINICAL DATA FOR THE ONGOING PHASE 1 CLINICAL STUDY WITH DCC-3014 AND AN UPDATE ON FUTURE DEVELOPMENT PLANS.DECIPHERA - DECIPHERA PHARMACEUTICALS PLANS EXPANSION OF ONGOING PHASE 1 STUDY TO INCLUDE PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS.DECIPHERA PHARMACEUTICALS INC - DCC-3014 DEMONSTRATES TOLERABILITY, PHARMACOKINETICS AND BIOMARKER MECHANISTIC PROOF-OF-CONCEPT (MPOC) IN PATIENTS.DECIPHERA PHARMACEUTICALS INC - BIOMARKER DATA DEMONSTRATED STRONG TARGET ENGAGEMENT OF CSF1R,.DECIPHERA - IN DOSE-COHORT THAT RECEIVED 10 MG QD, CLINICALLY ASYMPTOMATIC LABORATORY VALUES RECORDED AS DOSE-LIMITING TOXICITIES IN 2 OF 7 PATIENTS.  Full Article

Deciphera Pharmaceuticals Reports Third Quarter Loss Per Share $0.65
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.65.Q3 EARNINGS PER SHARE VIEW $-0.65 -- THOMSON REUTERS I/B/E/S.ENDED Q3 2018 WITH CASH AND CASH EQUIVALENTS OF $321 MILLION.  Full Article

Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Study Results With Dcc-2618
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS REPORTS UPDATED PRELIMINARY PHASE 1 CLINICAL STUDY RESULTS WITH DCC-2618 AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) 2018 CONGRESS.DECIPHERA PHARMACEUTICALS INC - OBJECTIVE RESPONSE RATES AND DISEASE CONTROL RATES OBSERVED CONTINUE TO EXCEED PREVIOUSLY PUBLISHED RESULTS.DECIPHERA PHARMACEUTICALS INC - RESULTS DEMONSTRATE POTENTIAL FOR IMPROVED AND DURABLE CLINICAL OUTCOMES IN PATIENTS WITH LESS ADVANCED DISEASE.  Full Article

Deciphera Pharmaceuticals Files For Mixed Shelf Of Up To $400 Mln
Tuesday, 2 Oct 2018 

Oct 1 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $400 MILLION - SEC FILING.  Full Article

Deciphera Pharma Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Jun 2018 

June 4 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.75 MILLION COMMON SHARES.  Full Article

Deciphera Pharmaceuticals Reports Q1 Loss Per Share $0.66
Wednesday, 9 May 2018 

May 8 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.66.Q1 EARNINGS PER SHARE VIEW $-0.65 -- THOMSON REUTERS I/B/E/S."STUDY IN 2(ND)-LINE GIST ON TRACK TO COMMENCE LATER THIS YEAR".  Full Article

Deciphera Pharmaceuticals Q3 loss $5.85 per share​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Deciphera Pharmaceuticals Inc : :Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights.Qtrly loss $5.85 per share​.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article